Irinotecan Injection

96 interactions 769 cited references

Also sold as: Camptosar Camptosar® Onivyde

About Irinotecan Injection

Irinotecan is used alone or in combination with other medications to treat colon or rectal cancer (cancer that begins in the large intestine). Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It works by stopping the growth of cancer cells. Read the full Irinotecan Injection drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Rubella Virus Vaccine, Live Smallpox Monkeypox Vaccine Typhoid Vaccine Varicella Virus Vaccine, Live Yellow Fever Vaccine Atazanavir

14 Contraindicated 73 Major 9 Moderate

All (96) Contraindicated (14) Major (73) Moderate (9)

Major

Irinotecan Injection Nefazodone Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Nelfinavir Viracept Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Netupitant Increased exposure to chemotherapy agent and increased risk of side effects Details Irinotecan Injection Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Irinotecan Injection Pacritinib Vonjo® Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse reactions Details Irinotecan Injection Paritaprevir Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Irinotecan Injection Phenytoin Dilantin Reduced irinotecan exposure and reduced irinotecan active metabolite exposure Details Irinotecan Injection Posaconazole Noxafil Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Irinotecan Injection Probenecid Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Quizartinib Vanflyta Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse reactions Details Irinotecan Injection Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Irinotecan Injection Ribociclib Kisqali Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Rifabutin Mycobutin Reduced irinotecan exposure and reduced irinotecan active metabolite exposure Details Irinotecan Injection Rifampin Rifadin Reduced irinotecan exposure and reduced irinotecan active metabolite exposure Details Irinotecan Injection Rifapentine Priftin Reduced irinotecan exposure and reduced irinotecan active metabolite exposure Details Irinotecan Injection Ritonavir Norvir Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Irinotecan Injection Sacituzumab Govitecan-Hziy Increased risk of adverse reactions Details Irinotecan Injection Saquinavir Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection St John's Wort Reduced irinotecan exposure and reduced irinotecan active metabolite exposure Details Irinotecan Injection Tafamidis Vyndamax Increased BCRP substrate exposure and an increased risk of the substrate-related toxicities Details Irinotecan Injection Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Irinotecan Injection Tedizolid Phosphate Sivextro Increased BCRP substrates exposure and an increased risk of BCRP substrates-related adverse reactions Details Irinotecan Injection Telaprevir Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Telithromycin Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Teriflunomide Aubagio Increased exposure of BCRP substrate Details Irinotecan Injection Troleandomycin Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Tucatinib Tukysa Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Irinotecan Injection Vadadustat Vafseo Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse effect Details Irinotecan Injection Vimseltinib Romvimza Increased risk of BCRP substrate exposure Details Irinotecan Injection Voriconazole Vfend Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.